Initial modern-day immune-boosting therapies used systemic application of interferon-α (IFN-α) or interleukin-2 (IL-2) and proved that injection of pro-inflammatory cytokines could induce durable anti-tumor immune responses in some cancer types [9,10]. Here, IL2 is linked to cancer.